Hey I am on Medial • 4m
As someone who actually used both Cepheid and Truenat systems during COVID (I work in hospital administration), there are significant differences. Cepheid is more user-friendly with fully integrated cartridges but costs 3-4x more per test. Truenat requires more manual steps but is much more cost-effective. In wealthy countries, Cepheid wins easily. In resource-limited settings, Truenat has a massive advantage. The question for investors is where the growth will come from. If Molbio stays focused on emerging markets, they could build a sustainable business. If they try to compete head-on with Cepheid in developed markets, they'll likely fail. Their valuation assumes they'll succeed everywhere, which is unrealistic.
•
Helixworks Technologies • 4m
From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. 💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. 🔬 Their Truenat platform, is a battery-power
See More•
Helixworks Technologies • 4m
Why qPCR & Phenotypic Testing Must Be Displaced? – Part III This is the third part of a deep dive into why qPCR & phenotypic testing need to be replaced. In Part I, I covered the limitations of current diagnostics & why incremental improvements aren
See MorePassionate about Pos... • 4m
The Future is Being Built Right Now – And This is MASSIVE $20 billion. That’s the valuation Safe Superintelligence is now chasing—a 4X jump in just a few months. This isn’t just another AI startup raising capital. This is the birth of something monu
See MoreHistory always repea... • 6m
🐶 Department of Government Efficiency (DOGE), led by Elon Musk, continues its work. This time, attention has turned to the fact that the Joe Biden administration is spending massive amounts of money to "eliminate racism" in animals. 🐾 They discove
See MoreDownload the medial app to read full posts, comements and news.